Nordic Nanovector And Affibody Collaborate On Advanced Radio-Immunotherapies Program For Multiple Myeloma
OSLO, Norway & SOLNA, Sweden--(BUSINESS WIRE)--Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant the project will combine Affibody’s proprietary platforms with Nordic Nanovector's radioimmunotherapy technology. The project aims to provide documentation necessary to start GMP manufacturing of the Affibody®-based RIT and subsequently start clinical trials. The companies have been awarded approximately €1m in total by Vinnova in Sweden and The Norwegian Research Council in Norway.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.